


## Introduction

Bone anomalies have posed a significant global burden, underscoring the need for deeper insights into bone biomechanics, pathophysiology, and regenerative strategies [1]. Conventional bone tissue engineering relies on exogenous agents, such as growth factors (e.g., BMP2) and corticosteroids (e.g., dexamethasone), to promote osteogenesis, however, limitations exist, including a lack of differentiation specificity, safety concerns and side effects [2]. We have developed a nanovibrational bioreactor capable of inducing mesenchymal stem cell (MSC) osteogenesis at a 30 nm amplitude (NK30, 1 kHz) without any chemical supplementation. Preliminary data suggest enhanced osteogenic differentiation and optimal reactive oxygen species (ROS) and inflammatory signalling at 90 nm (NK90). Considering this, we aim to investigate high-amplitude nanovibration (100 nm, NK100, 1 kHz) to elucidate its effects on MSC osteogenesis, redox balance, and inflammatory pathways [3].

## Aims and objectives

The study aims to investigate the effects of high amplitude nanostimulation [100 nm (NK100, 1 kHz)] as compared to the standard 30 nm, 1 kHz on:

1. The expression profiles of osteogenic differentiation, inflammation markers.
2. Phenotype change, followed by emphasis on respiration-related ROS and inflammation.




## Methodology

Human Bone marrow-derived primary MSCs (hBMSCs) were cultured at NK30 and NK100 with osteogenic media (OGM), basal control, and stress conditions (10  $\mu$ M TBHP, 0.1  $\mu$ M Doxorubicin) for 4 and 6 weeks. In-cell western was performed to quantify TOM20, phospho-p38/p38 ratio, osteopontin (OPN), and osteocalcin (OCN) protein expression. Late-stage matrix mineralization was determined by Von Kossa staining. Flow cytometry was used to analyse total ROS production, while in-cell western assessed protein expression of sirtuin 3 (SIRT3) glutathione reductase (GSR), superoxide dismutase 1 (SOD1), and catalase. DNA damage was determined based on the number of YH2AX-foci using immunostaining. Secretory profiling of inflammatory cytokines (IL-6, TNF- $\alpha$ , IL-8) was performed using ELISA.


## Results

### (1) Osteogenic differentiation marker expression




**Fig. 1. Protein expression levels of mitochondrial and late osteogenic differentiation markers.** hBMSCs grown at NK30, NK100, OGM, and control were examined for (A) TOM20 and p-p38/p38 at 7 days, (B) OPN and OCN protein expression at 28 days. Unpaired t-test was performed relative to control for statistical analysis. (Mean $\pm$ SEM, N=3) \*p $\leq$ 0.05 and \*\*p $\leq$ 0.01 statistical significances were observed.

### (4) Antioxidation signalling marker expression




**Fig. 4. Protein expression levels of antioxidation markers.** hBMSCs grown at NK30, NK100, OGM, and control were examined for sirtuin 3 (SIRT3), glutathione reductase (GSR), superoxide dismutase 1 (SOD1), and catalase at 7 days. One-WAY ANOVA was performed for statistical analysis. (Mean $\pm$ SEM, N=3) \*p $\leq$ 0.05 and \*\*p $\leq$ 0.01 statistical significances were observed.

### (2) Late-stage matrix mineralisation




**Fig. 2. Quantification of late-stage matrix mineralisation.** Both NK30 and NK100 exhibited considerable deposition of hydroxyapatite or calcium phosphate minerals at 42 days, as indicated by an increased % area of mineralisation. One-WAY ANOVA was performed for statistical analysis. (Mean $\pm$ SEM, N=3) \*p $\leq$ 0.05, \*\*p $\leq$ 0.01 and \*\*\*\*p $\leq$ 0.0001 statistical significances were observed.

### (5) DNA damage (YH2AX formation)




**Fig. 5. Assessment of DNA damage via YH2AX formation.** Representative immunofluorescence images showing YH2AX foci (red), cytoskeleton (green) and nuclei (blue) in hBMSCs grown at NK30, NK100, OGM, and control for 7 days. Cells treated with 0.1  $\mu$ M doxorubicin were used as a positive control for DNA damage. Decreased YH2AX foci indicates less DNA damage. Kruskal-Wallis test was performed for statistical analysis. (Mean $\pm$ SEM, N=3) \*p $\leq$ 0.05, \*\*p $\leq$ 0.01, \*\*\*p $\leq$ 0.001 and \*\*\*\*p $\leq$ 0.0001 statistical significances were observed.

### (3) Total ROS production



**Fig. 3. Comparative estimation of ROS-positive cells.** hBMSCs grown at NK30, NK100, OGM, and control were analysed for total ROS production levels at 7, 14 and 28 days. Cells treated with TBHP served as a positive control for oxidative stress. (A) Representative FSC-A (x-axis) versus SSC-A (y-axis) plot showing the total viable cell population, followed by FSC-A (x-axis) versus FSC-H (y-axis) for doublet exclusion. (B) Comparison of conditions based on the % of ROS-positive cells normalised to TBHP. One-Way ANOVA was performed for statistical analysis. (Mean $\pm$ SEM, N=3) \*p $\leq$ 0.05, \*\*p $\leq$ 0.01 and \*\*\*p $\leq$ 0.001 statistical significances were observed.

### (6) Pro-inflammatory cytokine profiling



**Fig. 6. Proinflammatory cytokine profiling.** hBMSCs grown at NK30, NK100, OGM, and control were analysed for the secreted levels of (A) IL-6, (B) TNF $\alpha$ , and (C) IL-8 at 1-2 and 3-4 weeks. Comparison of conditions is based on cytokine concentration (pg/mg). Kruskal-Wallis test was performed for statistical analysis. (Mean $\pm$ SEM, N=3) No statistical significance was observed.

## Conclusion and future work

Our findings suggest that high-amplitude nanostimulation may promote enhanced MSC osteogenesis, likely under eustress or mild physiological stress and optimal inflammatory conditions. This is supported by considerable late-stage matrix mineralisation, optimal total ROS production, and non-significant secretion of pro-inflammatory factors, which is further reflected by the decreased expression of antioxidant markers. However, to substantiate these outcomes, we aim to employ RNA sequencing to investigate relevant signalling pathways, along with collagen gel contraction assay and recipher assay to assess oxygen consumption rate (OCR).

## References

- [1] Shen Y *et al.* Front. Endocrinol. 13: 882241, 2022.
- [2] Childs PG *et al.* Biochem. J. 477: 3349–3366, 2020.
- [3] Orapiriyakul W *et al.* A.C.S. Nano. 14: 10027–10044, 2020.

## Acknowledgement

We acknowledge EPSRC for the grant EP/X013057/1 and thank Dr. Vineetha Jayawarna, Dr. Al Macdonald, and Mrs. Merna Maung for their support with technical assistance and consumables.